Effect of Tramadol Versus Morphine on PD1 and PD1-ligand in Patients With Chronic Cancer Pain

Last updated: January 13, 2021
Sponsor: Assiut University
Overall Status: Active - Recruiting

Phase

2/3

Condition

Cancer Pain

Acute Pain

Pain

Treatment

N/A

Clinical Study ID

NCT04589494
493
  • Ages 18-70
  • All Genders

Study Summary

this work is looking for comparison between the effect of tramadol versus morphine on PD1 and PD1-ligand in patients with chronic cancer pain

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • patients with cancer pain of varying etiology,
  • documented metastatic cancer, currently on step I WHO ladder and whose painnecessitates a shift to step II,
  • those who have never received radiotherapy, chemotherapy, or immunosuppressive drugs, -- and in good general and nutritional condition and without infectious diseases atthe time of investigation.

Exclusion

Exclusion Criteria:

  • abnormal hepatic, renal, and pulmonary function, gastrointestinal pathology, and
  • those with cerebral metastases and/or psychological disorders,
  • patients with contraindication to morphine or tramadol according to their respectivedata sheets, and
  • patients who could not complete the diary information correctly.

Study Design

Total Participants: 15
Study Start date:
April 16, 2020
Estimated Completion Date:
May 31, 2021

Study Description

The use of opioids is the mainstay in the treatment of many types of chronic pain, including cancer and non-cancer-related pain]. Opioids are known to suppress immune function following both acute and chronic administration; however, they appear to be different according to the schedule of administration as well as the state of the organism. Programmed death-1 (PD-1, also known as CD279) belongs to the CD28 receptor superfamily. It is an inhibitory receptor, and its expression is upregulated on activated leukocytes, resulting in an inhibited immune response. PD-1 interacts with two ligands: programmed death ligand-1 (PD-L1, also referred to as B7-H1) and programmed death ligand-2 (PD-L2, also known as B7-DC). PD-L2 is expressed mainly on activated dendritic cells (DCs) and macrophages, whereas PD-L1 is distributed widely. In addition to immune cells, some subsets of tumor cells also express PD-L1 to escape from immunosurveillance. It has been reported that the PD-1/PD-L1 pathway could be activated by surgical stress.

Connect with a study center

  • Assiut University

    Assiut, 171516
    Egypt

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.